Oral components

Abstract

This invention relates to an oral composition that contains an azulene compound while effectively suppressing discoloration of the composition itself. [Solution] The following components (A) and (B): (A) One or more azulene compounds selected from azulene, azulene sulfonic acid and its salts, and guaiazulene. (B) β-Glycyrrhetinic acid An oral composition containing [a specific ingredient].

Description

Technical Field

[0001] The present invention relates to an oral composition.

Background Art

[0002] Conventionally, compounds such as azulene are known as one of the components that bring about desired pharmacological effects such as anti-inflammatory and bactericidal effects, and are used in various compositions for application in the oral cavity.

[0003] For example, Patent Document 1 discloses a liquid composition containing an azulene sulfonate having an anti-inflammatory effect, cetylpyridinium, and a weakly acidic substance, and attempts to suppress the adsorption of the azulene sulfonate to the inner wall of a plastic container. Further, Patent Document 2 discloses an oral composition containing azulene sulfonic acid and / or its salt, a quaternary ammonium salt, a monoterpene, and propylene glycol in specific amounts, and aims to suppress the formation of insoluble matter after storage.

Prior Art Documents

Patent Documents

[0004]

Patent Document 1

Patent Document 2

Summary of the Invention

Problems to be Solved by the Invention

[0005] By the way, azulene compounds such as azulene and sodium azulene sulfonate are likely to cause photodegradation due to low photo stability, and there is a risk of discoloration during storage of the composition. However, none of the above patent documents have paid any attention to the discoloration of the composition itself caused by such azulene compounds, and no consideration has been made at all.

[0006] Therefore, the present invention relates to an oral composition that contains an azulene compound while effectively suppressing discoloration of the composition itself. [Means for solving the problem]

[0007] Therefore, the inventors conducted diligent research to solve the above problems and found an oral composition that contains an azulene compound and β-glycyrrhetinic acid, which effectively enhances the photostability of the azulene compound and effectively suppresses discoloration during storage of the composition.

[0008] In other words, the present invention comprises the following components (A) and (B): (A) One or more azulene compounds selected from azulene, azulene sulfonic acid and its salts, and guaiazulene. (B) β-Glycyrrhetinic acid This invention provides an oral composition containing [a specific ingredient]. Furthermore, the present invention relates to the following components (A) and (B): (A) One or more azulene compounds selected from azulene, azulene sulfonic acid and its salts, and guaiazulene. (B) β-Glycyrrhetinic acid This invention provides a method for suppressing discoloration of oral compositions by adding [a specific substance]. [Effects of the Invention]

[0009] The oral composition of the present invention effectively enhances the photostability of the azulene compound and effectively suppresses unwanted discoloration of the composition during storage. Therefore, the container for filling the oral composition is not limited to being made of a light-shielding material, and the freedom to select the type of container is increased. Furthermore, the anti-inflammatory effect can be effectively and synergistically enhanced by azulene compounds and β-glycyrrhetinic acid, making it highly useful as a composition for application in the oral cavity. [Brief explanation of the drawing]

[0010] [Figure 1] In evaluating the discoloration suppression effect, the images show photographs of the oral composition before and after storage, filled in transparent containers. Figure 1(A) shows the photograph before storage, where (a1) shows the oral composition of Example 7, (a2) shows the oral composition of Comparative Example 3, and (a3) ​​shows the oral composition of Comparative Example 4. Figure 1(B) shows the photograph after storage, where (b1) shows the oral composition of Example 7, (b2) shows the oral composition of Comparative Example 3, and (b3) shows the oral composition of Comparative Example 4. [Modes for carrying out the invention]

[0011] The present invention will be described in detail below. The oral composition of the present invention contains, as component (A), one or more azulene compounds selected from azulene, azulene sulfonic acid and its salts, and guaiazulene. Because such component (A) has low photostability, it is prone to photodegradation, which can cause discoloration of the composition. However, with the oral composition of the present invention, photostability can be effectively increased to effectively suppress discoloration of the composition, and the reduction of the anti-inflammatory effect inherent in component (A) can be effectively avoided. Rather, together with β-glycyrrhetinic acid, component (B) described later, the anti-inflammatory effect can be effectively and synergistically enhanced.

[0012] Examples of azulene sulfonates include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts; metal salts other than alkali metal salts and alkaline earth metal salts such as aluminum; ammonium salts; carboxylate salts such as acetate, palmitate, stearate, fumarate, and citrate; organic amine salts such as methylamine salt, triethylamine salt, triethanolamine salt, morpholine salt, piperazine salt, pyrrolidine salt, tripyridine salt, and picoline salt; and inorganic salts such as hydrochloride salt, sulfate salt, nitrate salt, hydrobromide salt, and phosphate salt.

[0013] Among the component (A), from the viewpoints of exerting a sufficient discoloration suppressing effect by the component (B) described later and synergistically enhancing the anti-inflammatory action, one or more selected from azulene and azulenesulfonate are preferable, azulenesulfonate is more preferable, and sodium azulenesulfonate is even more preferable.

[0014] From the viewpoints of effectively exerting the discoloration suppressing effect and synergistically enhancing the anti-inflammatory action, the content of the component (A) in the oral composition of the present invention is preferably 0.001% by mass or more, more preferably 0.005% by mass or more, even more preferably 0.01% by mass or more, still more preferably 0.015% by mass or more, preferably 0.03% by mass or less, more preferably 0.028% by mass or less, and even more preferably 0.025% by mass or less. And the content of the component (A) in the oral composition of the present invention is preferably 0.001% by mass or more and 0.03% by mass or less, more preferably 0.005 to 0.028% by mass, even more preferably 0.01 to 0.028% by mass, and still more preferably 0.015 to 0.025% by mass.

[0015] The oral composition of the present invention contains β-glycyrrhetinic acid as the component (B). β-glycyrrhetinic acid is obtained by hydrolyzing glycyrrhizic acid obtained from licorice and the like, and is also known as a kind of medicinal ingredient having an anti-inflammatory action and the like. By containing this as the component (B), unexpectedly, the photostability of the component (A) can be effectively enhanced to sufficiently exert the discoloration suppressing effect in the composition, and at the same time, a synergistic enhancement of the anti-inflammatory action with such component (A) is also made possible.

[0016] From the viewpoint of effectively exhibiting a discoloration-inhibiting effect and ensuring the expression of excellent anti-inflammatory effects, the content of component (B) in the oral composition of the present invention is preferably 0.0005% by mass or more, more preferably 0.001% by mass or more, even more preferably 0.002% by mass or more, even more preferably 0.003% by mass or more, even more preferably 0.005% by mass or more, even more preferably 0.008% by mass or more, preferably 0.6% by mass or less, more preferably 0.5% by mass or less, even more preferably 0.45% by mass or less, even more preferably 0.4% by mass or less, even more preferably 0.35% by mass or less, and even more preferably 0.3% by mass or less. Furthermore, the content of component (B) in the oral composition of the present invention is preferably 0.0005 to 0.6% by mass, more preferably 0.001 to 0.5% by mass, even more preferably 0.002 to 0.45% by mass, even more preferably 0.003 to 0.4% by mass, even more preferably 0.05 to 0.35% by mass, and even more preferably 0.008 to 0.3% by mass.

[0017] The mass ratio ((A) / (B)) of the content of component (A) to the content of component (B) is preferably 0.0017 or more, more preferably 0.002 or more, even more preferably 0.0035 or more, even more preferably 0.005 or more, preferably 60 or less, more preferably 30 or less, even more preferably 6 or less, and even more preferably 3 or less, from the viewpoint of effectively exhibiting a discoloration-inhibiting effect and enabling a synergistic enhancement of the anti-inflammatory effect. Furthermore, the mass ratio ((A) / (B)) of the content of component (A) to the content of component (B) is preferably 0.0017 or more and 60 or less, more preferably 0.002 to 30, even more preferably 0.0035 to 6, and even more preferably 0.005 to 3.

[0018] From the perspective of further enhancing the synergistic enhancement effect of the discoloration suppression effect and the anti-inflammatory action, the oral composition of the present invention preferably further contains, as component (C), one or more fragrance components selected from eugenol, geraniol, linalool, methyl salicylate, and camphor. Among component (C), from the perspective of exerting an effective and efficient discoloration suppression effect and ensuring the expression of an excellent anti-inflammatory action, one or more selected from eugenol, geraniol, linalool, and methyl salicylate are preferable, and one or two selected from eugenol and geraniol are more preferable.

[0019] From the perspective of effectively exerting the discoloration suppression effect and ensuring the expression of an excellent anti-inflammatory action, the content of component (C) in the oral composition of the present invention is preferably 0.0001% by mass or more, more preferably 0.0005% by mass or more, still more preferably 0.001% by mass or more, even more preferably 0.002% by mass or more, even more preferably 0.003% by mass or more, even more preferably 0.004% by mass or more, preferably 1% by mass or less, more preferably 0.8% by mass or less, still more preferably 0.5% by mass or less, even more preferably 0.4% by mass or less, even more preferably 0.3% by mass or less, and even more preferably 0.2% by mass or less. And the content of component (C) in the oral composition of the present invention is preferably 0.0001 to 1% by mass, more preferably 0.0005 to 0.8% by mass, still more preferably 0.001 to 0.5% by mass, even more preferably 0.002 to 0.4% by mass, even more preferably 0.003 to 0.3% by mass, and even more preferably 0.004 to 0.2% by mass.

[0020] The mass ratio ((A) / (C)) of the content of component (A) to the content of component (C) is preferably 0.001 or more, more preferably 0.01 or more, even more preferably 0.03 or more, preferably 15 or less, more preferably 10 or less, and even more preferably 5 or less, from the viewpoint of effectively exhibiting a discoloration-inhibiting effect and ensuring the expression of excellent anti-inflammatory effects. Furthermore, the mass ratio ((A) / (C)) of the content of component (A) to the content of component (C) is preferably 0.001 to 15, more preferably 0.01 to 10, and even more preferably 0.03 to 5.

[0021] The oral composition of the present invention contains water. In this invention, water refers to the total water content in the oral composition, including not only purified water or the like that blended into the oral composition, but also the water contained in each of the blended components. By including such water, the above-mentioned components are dissolved or dispersed well, the photostability of component (A) is effectively enhanced to fully exhibit a discoloration-inhibiting effect, a synergistic enhancement of the anti-inflammatory effects of component (A) and component (B) is possible, and the desired effects of component (A) can also be effectively brought about.

[0022] Specifically, when the oral composition of the present invention is a toothpaste composition such as a toothpaste or tooth powder, the water content in the oral composition of the present invention is preferably 5% by mass or more, more preferably 10% by mass or more, even more preferably 25% by mass or more, preferably 60% by mass or less, more preferably 55% by mass or less, and even more preferably 50% by mass or less. Furthermore, when the oral composition of the present invention is a liquid oral composition such as a mouthwash or liquid toothpaste, the water content in the oral composition of the present invention is preferably 60% by mass or more, more preferably 80% by mass or more, even more preferably 90% by mass or more, preferably 99.7% by mass or less, more preferably 99.5% by mass or less, and even more preferably 99.4% by mass or less.

[0023] Furthermore, if the oral composition of the present invention is a toothpaste composition such as a toothpaste paste or toothpaste powder, its moisture content can be calculated from the amount of water added and the amount of water in the added components, but it can also be measured using, for example, a Karl Fischer moisture meter. As a Karl Fischer moisture meter, for example, a trace moisture measuring device (manufactured by Hiranuma Sangyo Co., Ltd.) can be used. With this device, 5g of the oral composition can be taken, suspended in 25g of anhydrous methanol, and 0.02g of this suspension can be taken out to measure its moisture content.

[0024] In addition to the above components, the oral composition of the present invention may contain one or more surfactants selected from anionic surfactants, cationic surfactants, nonionic surfactants, and amphoteric surfactants.

[0025] For example, as anionic surfactants, anionic surfactants other than sulfate esters, such as alkyl sulfates and polyoxyalkylene alkyl ether sulfates, are preferred. Specifically, examples include fatty acid salts such as oleates and laurates; alkyl sulfonates such as alkylbenzene sulfonates, α-olefin sulfonates, and hydroxyalkane sulfonates; alkyl phosphates such as alkyl phosphates; fatty acid ester salts of higher fatty acid sulfonated monoglycerides and isethionic acid; polyoxyethylene monoalkyl phosphates; N-acyl amino acids, N-acyl taurines, and one or more selected from these salts.

[0026] From the viewpoint of ensuring that the discoloration-inhibiting effect in the present invention is fully exerted and that excellent anti-inflammatory effects are achieved, the surfactant content in the oral composition of the present invention is usually 0.05% by mass or more, preferably 0.1% by mass or more, more preferably 0.3% by mass or more, usually 5% by mass or less, preferably 3% by mass or less, and more preferably 2% by mass or less. More specifically, when the oral composition of the present invention is a toothpaste composition such as a toothpaste or toothpaste powder, the amount of such surfactant in the oral composition of the present invention is preferably 0.3% by mass or more, more preferably 0.5% by mass or more, even more preferably 0.8% by mass or more, preferably 3% by mass or less, more preferably 2.5% by mass or less, and even more preferably 2% by mass or less. Furthermore, when the oral composition of the present invention is a liquid oral composition such as a mouthwash or liquid toothpaste, the amount of such surfactant in the oral composition of the present invention is preferably 0.05% by mass or more, more preferably 0.1% by mass or more, even more preferably 0.2% by mass or more, preferably 2% by mass or less, more preferably 1.6% by mass or less, and even more preferably 1.4% by mass or less.

[0027] When the oral composition of the present invention is a toothpaste composition such as a toothpaste paste or a toothpaste powder, in order to provide an appropriate viscosity and ensure a good feel as a toothpaste composition, a binder may be included in addition to the above components. Specifically, such binders include, for example, polymer-based binders such as carboxyvinyl polymer and acrylic acid / (meth)acrylate alkyl copolymer; hydroxycellulose derivatives such as hydroxyethylcellulose, hydroxypropylcellulose, and hydroxypropyl methylcellulose; and one or more selected from sodium carboxymethylcellulose, ethylcellulose, sodium alginate, carrageenan, xanthan gum, sodium polyacrylate, pectin, agar, tragacanth gum, gum arabic, guar gum, karaya gum, locust bean gum, gela gum, tamarid gum, psyllium seed gum, etc. In particular, one or more selected from sodium carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, sodium alginate, carrageenan, and xanthan gum are preferred.

[0028] When the oral composition of the present invention is a toothpaste composition such as a toothpaste or a toothpaste powder, the amount of binder in the oral composition of the present invention is preferably 0.05 to 3% by mass, more preferably 0.1 to 2.5% by mass, and even more preferably 0.3 to 2% by mass.

[0029] When the oral composition of the present invention is a toothpaste or toothpaste powder, in order to provide an appropriate viscosity and ensure a good feel as a toothpaste composition, it may also contain water-insoluble powders in addition to the above components. Note that "water-insoluble" means that the amount that dissolves in 100g of water (at 20°C) is 1g or less.

[0030] Examples of such water-insoluble powders include, for example, one or more selected from hydrated silicic acid, anhydrous silicic acid, silica gel, aluminosilicate, zirconosilicate, calcium phosphate such as dicalcium phosphate and tricalcium phosphate, magnesium phosphate, calcium carbonate such as light calcium carbonate and heavy calcium carbonate, aluminum hydroxide, alumina, zeolite, calcium pyrophosphate, sodium polyphosphate, magnesium carbonate, and magnesium acetate, and may be in hydrated or anhydrous form as appropriate.

[0031] When the oral composition of the present invention is a toothpaste composition such as a toothpaste or a toothpaste powder, the content of water-insoluble powder in the oral composition of the present invention is preferably 0.1 to 35% by mass, more preferably 0.5 to 30% by mass, even more preferably 1 to 25% by mass, even more preferably 5 to 20% by mass, and still more preferably 8 to 15% by mass.

[0032] The oral composition of the present invention may further contain one or more sugar alcohols selected from erythritol, sorbitol, mannitol, and xylitol, from the viewpoint of fully exhibiting the discoloration-inhibiting effect in the present invention without inhibiting it, and from the viewpoint of ensuring the expression of excellent anti-inflammatory effects. The content of such sugar alcohols in the oral composition of the present invention is preferably 1 to 50% by mass, more preferably 2 to 48% by mass, and even more preferably 3 to 46% by mass. More specifically, when the oral composition of the present invention is a toothpaste composition such as a toothpaste or a toothpaste powder, the content of such sugar alcohol in the oral composition of the present invention is preferably 7% by mass or more, more preferably 18% by mass or more, even more preferably 35% by mass or more, preferably 50% by mass or less, more preferably 48% by mass or less, and even more preferably 46% by mass or less. Furthermore, when the oral composition of the present invention is a liquid oral composition such as a mouthwash or liquid toothpaste, the content of such sugar alcohol in the oral composition of the present invention is preferably 1% by mass or more, more preferably 2% by mass or more, even more preferably 3% by mass or more, preferably 30% by mass or less, more preferably 25% by mass or less, and even more preferably 20% by mass or less.

[0033] The oral composition of the present invention may further contain one or more polyhydric alcohols selected from glycerin, propylene glycol, and polyethylene glycol, from the viewpoint of fully exhibiting the discoloration-inhibiting effect in the present invention without inhibiting it, and from the viewpoint of ensuring the expression of excellent anti-inflammatory effects. The content of such polyhydric alcohols in the oral composition of the present invention is preferably 0.1 to 10% by mass, more preferably 0.5 to 9% by mass, and even more preferably 1 to 7% by mass. More specifically, for example, if the oral composition of the present invention is a toothpaste composition such as a toothpaste or toothpaste powder, the content of such polyhydric alcohol in the oral composition of the present invention is preferably 1% by mass or more, more preferably 3.5% by mass or more, even more preferably 4% by mass or more, preferably 10% by mass or less, more preferably 9% by mass or less, and even more preferably 7% by mass or less.

[0034] The oral composition of the present invention may contain, in addition to the above-mentioned components, pH adjusters such as sodium fluoride, stannous fluoride, or sodium monofluorophosphate, as well as sodium hydroxide; disinfectants; fragrances other than component (B); sweeteners; preservatives, etc., to the extent that they do not impair the effects of the present invention.

[0035] The pH of the oral composition of the present invention at 25°C is preferably 5 or higher, more preferably 5.5 or higher, even more preferably 6 or higher, preferably 9 or lower, more preferably 8.5 or lower, even more preferably 8 or lower, even more preferably 7.5 or lower, and still more preferably 7 or lower, from the viewpoint of effectively exhibiting a discoloration-inhibiting effect and ensuring the expression of excellent anti-inflammatory effects. Furthermore, the pH of the oral composition of the present invention at 25°C is preferably 5 to 9, more preferably 5.5 to 8.5, even more preferably 6 to 8, even more preferably 6 to 7.5, and still more preferably 6 to 7.

[0036] The viscosity of the oral composition of the present invention at 25°C is preferably 1000 dPa·s or more, more preferably 1500 dPa·s or more, even more preferably 2000 dPa·s or more, preferably 10000 dPa·s or less, more preferably 8000 dPa·s or less, and even more preferably 7000 dPa·s or less. Furthermore, the viscosity of the oral composition of the present invention at 25°C is preferably 1000 to 10000 dPa·s, more preferably 1500 to 8000 dPa·s, and even more preferably 2000 to 7000 dPa·s. The viscosity of oral compositions refers to the value measured using a digital viscometer (TVB-10 viscometer, manufactured by Toki Sangyo Co., Ltd.) and a T-bar stage (TS-20, manufactured by Toki Sangyo Co., Ltd.) under the conditions of rotor TC, rotation speed of 2.5 rpm, and 1 minute.

[0037] The container for filling the oral composition of the present invention is not limited to a container made of a light-shielding material such as a metallic layer of aluminum, but can also be made of a material without a metallic layer or a transparent material, as it does not require consideration of the discoloration of the oral composition over time. Therefore, the oral composition of the present invention is a highly useful oral composition because it allows for greater freedom in selecting the type of container for filling it.

[0038] Furthermore, the present invention is also highly useful as a method for suppressing discoloration of oral compositions containing the above component (A). That is, such a method involves the following component (A): (A) One or more azulene compounds selected from azulene, azulene sulfonic acid and its salts, and guaiazulene. (B) β-Glycyrrhetinic acid This method involves adding a substance to suppress discoloration of an oral composition. The content and quantitative relationships of each component are the same as described above.

[0039] With the method of the present invention, even if the oral composition containing the above component (A) is filled into a container made of a material that does not have a metallic layer or a container made of a transparent material, discoloration of the oral composition can be effectively suppressed while ensuring the expression of a synergistically enhanced high anti-inflammatory effect. [Examples]

[0040] The present invention will be described in detail below based on examples. Unless otherwise specified in the table, the content of each component is expressed in mass percent.

[0041] [Examples 1-8, Comparative Examples 1-5] Each oral composition (viscosity at 25°C: approximately 2500 dPa·s) was prepared according to the formulations shown in Tables 1-3. Next, the discoloration-inhibiting effect of each obtained oral composition was evaluated according to the method described below. The oral compositions shown in Tables 1 and 2 correspond to toothpaste compositions, and the oral compositions shown in Table 3 correspond to liquid oral compositions. A corresponding evaluation method for the discoloration-inhibiting effect was used for each. The results are shown in Tables 1-3.

[0042] Evaluation of the discoloration suppression effect 1. Evaluation of the discoloration-inhibiting effect when the oral composition is a toothpaste composition. Ten g of each obtained oral composition was filled into a transparent container (container body material: polystyrene) and stored for one week at 25°C while being illuminated by a fluorescent lamp with a color temperature of 6700K. The L*, a*, and b* values ​​were measured for both the oral composition before and after storage using a spectrophotometer (CM-700d, manufactured by Konica Minolta Optics, Inc.). The color difference formula (ΔE*ab = [(ΔL*)) 2 +(Δa*) 2 +(Δb*) 2 The color difference before and after storage was calculated according to (1 / 2), and the discoloration suppression effect of each oral composition was calculated when the discoloration suppression effect of Comparative Example 1 was set to 0%.

[0043] 2. Evaluation of the discoloration suppression effect when the oral composition is a liquid oral composition. 80 mL of each obtained oral composition was filled into a transparent container (container body material: polyethylene terephthalate or polystyrene) and stored for one week at 25°C while being illuminated with an LED (Light Emitting Diode) light source lamp. For both the oral composition before and after storage, the absorbance (Abs) of each was measured using a microplate recorder (TECAN, Sunrise Rainbow Thermo, a tunable absorbance microplate reader) while the oral composition was still filled in its container. 577nm The values ​​were measured, and the percentage of color change was calculated by substituting the obtained values ​​into the following formula. Next, based on the obtained color change rate values, the color change rate values ​​of each oral composition were recalculated as the color change suppression effect (%) value, with the color change suppression effect of Comparative Example 4 set to 0%, and this was used as an evaluation index. Color change rate (%) = {(Absorbance of oral composition before storage Abs 577nm - Absorbance of oral composition after storage (Abs) 577nm Absorbance of oral composition before storage (Abs) 577nm}×100

[0044] Figure 1 shows photographs of both the oral composition before and after storage for Example 7 and Comparative Examples 3-4.

[0045] [Table 1]

[0046] [Table 2]

[0047] [Table 3]

[0048] [Evaluation test of anti-inflammatory effect] Following the formulations shown in Table 4, the components other than DMEM were prepared, and then DMEM was added to each component to dilute it 10-fold, thereby obtaining test solutions that resembled liquid oral compositions. Next, the anti-inflammatory effect of each obtained test solution was evaluated according to the method described below.

[0049] Normal human gingival fibroblasts were seeded in 24-well plates and cultured until confluence. Then, 5 μg / mL of lipopolysaccharide derived from Porphyromonas gingivalis was added to prepare test solutions 1-5. 1 ml of each test solution was added to a 24-well plate and cultured for 24 hours (n=3 for each). Next, total RNA was extracted from cultured cells using the RNeasy Mini kit (QIAGEN), and then cDNA was synthesized using High Capacity RNA to cDNA (Applied Biosystems). The gene expression level of Interluekin-6 (IL-6) was then quantified by quantitative PCR using a Taqman probe. The anti-inflammatory effect (%) of test solution 3 was calculated, with the IL-6 quantitative value of test solution 1 set to 0% and the IL-6 quantitative value of test solution 2 set to 100%. Similarly, the anti-inflammatory effect (%) of test solution 5 was calculated from the IL-6 quantitative values ​​of test solutions 1, 4, and 5. The results are shown in Table 4.

[0050] [Table 4]

[0051] Table 4 shows that test solution 2, which contains sodium azulene sulfonate (A) and β-glycyrrhetinic acid (B), exhibits an effective and synergistic enhancement of its anti-inflammatory effect.

Claims

1. The following components (A) and (B): (A) One or more azulene compounds selected from azulene, azulene sulfonic acid and its salts, and guaiazulene. (B) β-Glycyrrhetinic acid An oral composition containing [a specific ingredient].

2. The oral composition according to claim 1, wherein the mass ratio ((A) / (B)) of the content of component (A) to the content of component (B) is 0.0017 or more and 60 or less.

3. The oral composition according to claim 1 or 2, wherein the content of component (B) is 0.0005% by mass or more and 0.6% by mass or less.

4. The oral composition according to claim 1 or 2, wherein the content of component (A) is 0.001% by mass or more and 0.03% by mass or less.

5. The oral composition according to claim 1 or 2, further comprising one or more fragrance components (C) selected from eugenol, geraniol, linalool, methyl salicylate, and camphor.

6. The following components (A) and (B): (A) One or more azulene compounds selected from azulene, azulene sulfonic acid and its salts, and guaiazulene. (B) β-Glycyrrhetinic acid A method for suppressing discoloration of an oral composition by adding [a certain substance].

Images